Abstract |
Matrix metalloproteinases ( MMPs) have been implicated in several pathologies. At Abbott Laboratories, the matrix metalloproteinases inhibitor drug discovery program has focused on the discovery of a potent, selective, orally bioavailable MMP inhibitor for the treatment of cancer. The program evolved from early succinate-based inhibitors to utilizing in-house technology such as SAR by NMR to develop a novel class of biaryl hydroxamate MMP inhibitors. The metabolic instability of the biaryl hydroxamates led to the discovery of a new class of N-formylhydroxylamine (retrohydroxamate) biaryl ethers, exemplified by ABT-770 (16). Toxicity issues with this pre-clinical candidate led to the discovery of another novel class of retrohydroxamate MMP inhibitors, the phenoxyphenyl sulfones such as ABT-518 (19j). ABT-518 is a potent, orally bioavailable, selective inhibitor of MMP-2 and 9 over MMP-1 that has been evaluated in Phase I clinical trials in cancer patients.
|
Authors | Carol K Wada |
Journal | Current topics in medicinal chemistry
(Curr Top Med Chem)
Vol. 4
Issue 12
Pg. 1255-67
( 2004)
ISSN: 1568-0266 [Print] United Arab Emirates |
PMID | 15320725
(Publication Type: Journal Article, Review)
|
Chemical References |
- Matrix Metalloproteinase Inhibitors
- Protease Inhibitors
|
Topics |
- Animals
- Drug Design
- Drug Industry
- Humans
- Magnetic Resonance Spectroscopy
- Matrix Metalloproteinase Inhibitors
- Protease Inhibitors
(chemical synthesis, pharmacology)
- Structure-Activity Relationship
|